New Jersey lawmakers have taken a major step toward authorizing psilocybin-assisted therapy, advancing a bill that would allow adults with qualifying mental-health conditions to access the psychedelic compound under professional supervision.
The measure, approved by the Assembly Health Committee, shifts away from earlier proposals that would have legalized personal possession and use. Instead, the revised bill focuses solely on clinical, regulated therapeutic access — a move that disappointed some advocates but gained traction among legislators seeking a more controlled rollout.
A Regulated Pathway, Not a Free-For-All
Under the proposal, the Department of Health would oversee a multilayer licensing system, covering everything from manufacturing and testing to service centers and trained facilitators. Only adults aged 21 and older with specific mental-health or behavioral conditions — as determined by a licensed clinician — would qualify.
Patients wouldn’t simply show up, take a dose, and head home. The model requires preparation sessions before treatment and integration sessions afterwards to help individuals process and apply the experience in a therapeutic setting.
A new Psilocybin Behavioral Health Access and Services Advisory Board would guide everything from safety standards to facilitator training, dosage protocols, and qualification criteria.
Supporters Say It Fills a Critical Mental-Health Gap
During the committee hearing, advocates highlighted the potential benefits for people who have exhausted conventional treatment options for conditions such as PTSD, depression, and trauma. One of the bill’s sponsors emphasized the need to “give another option for people to heal and get better,” framing the measure as a lifeline for individuals stuck in cycles of distress.
Veteran groups also voiced strong support, noting the potential for psilocybin therapy to address “invisible wounds” that ripple beyond service members and into their families.
Equity Efforts Included
The legislation includes a social-equity program designed to make treatment more accessible for low-income residents. Proposed support includes fee reductions, financial assistance, and technical aid to help ensure affordability doesn’t become a barrier to care.
What Happens Next
The bill now heads to the Assembly Appropriations Committee. A matching Senate version has already advanced through two committees, suggesting momentum is building. If ultimately passed, New Jersey would become one of the few states to formally authorize a regulated therapeutic psilocybin program — potentially reshaping mental-health care on the East Coast.
Dabbin-Dad Newsroom
